Pediatric Type 1 Diabetes Cases With Exogenous Insulin Antibody Syndrome

Five pediatric patients with type 1 diabetes and exogenous insulin antibody syndrome were studied retrospectively at a single center from 2016 to 2026. Author Liang Zhang compiled data on demographics, clinical manifestations, laboratory findings, and treatment outcomes. The dataset includes longitudinal autoantibody profiles, thyroid function, immune parameters, and cytokines assessed at four time points.

Use Cases

• Analyze the relationship between insulin antibody titers and glycemic control metrics like TIR and TBR.
• Compare treatment outcomes across different insulin regimens, such as closed-loop pumps versus multiple daily injections.
• Investigate the effect of immunosuppressive therapy with mycophenolate mofetil on insulin antibody titers and glycemic stability.
• Examine clinical characteristics like age, C-peptide levels, and continuous glucose monitoring data across the five case studies.

Strengths

• Longitudinal data includes autoantibody profiles and immune parameters measured at four distinct time points.
• Detailed clinical outcomes are provided for each of the five cases, including specific treatment regimens and glycemic metrics.

Limitations

• Extremely small sample size of only five patients limits statistical power and generalizability.
• Data originates from a single center and lacks a control group, introducing potential bias.
• The 11.6 KB file size indicates a very limited scope, primarily containing summary case data.

Provenance

Source

Retrospective case series from a single clinical center.

Collection Method

Clinical data collection from pediatric patients diagnosed with T1DM and EIAS, supplemented by a literature review.

Time Range

January 2016 to January 2026.

Freshness

Data covers cases up to January 2026, with the dataset last updated in March 2026.